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Abstract 
 
Aims: Lewy body diseases are neuropathologically characterized by the abnormal 
accumulation of α-synuclein (α-syn) protein within vulnerable neurons. Although studies 
have evaluated α-syn in post-mortem brain tissue, previous findings have been limited by 
typically employing pan-α-syn antibodies that may not recognize disease-relevant forms of 
protein. We investigated the presence of α-syn species present in post-mortem brain tissues 
from Lewy body disease and Alzheimer’s disease. 
 
Methods: Soluble and insoluble/aggregated α-syn from frontal cortex of post-mortem brain 
tissues form Parkinson’s disease (PD), dementia with Lewy bodies (DLB), Alzheimer’s 
disease (AD) and aged control cases were sequentially extracted using buffers with 
increasing detergent concentrations. Enzyme-linked immunosorbent assay (ELISA) was used 
to quantify the levels of total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and 
pS129-α-syn). ELISA data were validated by western blot and compared to histological data 
from the same region of the contralateral hemisphere.  
 
Results: There was no difference in t-α-syn levels between groups in the aqueous soluble, 
detergent soluble or urea soluble tissue fractions. However, aqueous soluble non-
phosphorylated o-α-syn was increased not only in PD and DLB, but also in AD without 
neocortical Lewy bodies. In PD and AD, pS129-α-syn was increased in the detergent soluble 
tissue fragment and, in AD, this was positively correlated with the burden of tau pathology. 
Increased levels of urea soluble pS129-α-syn were demonstrated only in DLB tissue lysates 
but this did not correlate with Lewy body pathological burden.  
 
Conclusions: Taken together, these findings suggest that DLB have elevated levels of 
insoluble pS129-α-syn, but that increased levels of aqueous soluble o-α-syn and detergent 
soluble pS129-α-syn are also observed in PD and AD, suggesting different changes to α-syn 
across the spectrum of neurodegenerative proteopathies. 
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List of Abbreviations 
 
AD  Alzheimer’s disease 
DLB  Dementia with Lewy bodies 
ELISA  Enzyme-linked immunosorbent assay 
LBs  Lewy bodies 
LNs   Lewy neurites 
PBS  Phosphate buffered saline 
 
 
Introduction  
The aggregation of the protein alpha-synuclein (α-syn) is thought to be a central event 
in the pathogenesis of Lewy body diseases including Parkinson’s disease (PD) and dementia 
with Lewy bodies (DLB) (1-5). The central role of α-syn aggregation in the aetiology of 
Lewy body diseases has been established on the basis of mutations in the α-syn gene causing 
familial PD (6), polymorphisms in the α-syn gene contributing increased risk of idiopathic 
PD (7) and reduced levels of α-syn protein reducing the risk of Lewy body diseases (8). 
Lewy bodies (LBs) are intracytoplasmic aggregates of α-syn in vulnerable neurons, though 
aggregated α-syn may also be observed in neuronal processes as Lewy Neurites (LNs) (2). 
Although Lewy bodies are the neuropathological hallmark of Lewy body diseases such as PD 
and DLB (5), aggregated α-syn also accumulates in amyloid-β plaques in Alzheimer’s 
disease (AD) brain tissues (9). 
 
α-Syn is a 140 amino acid protein abundantly expressed in the human brain, making 
up approximately 1% of total brain protein (10, 11). The protein is primarily located at 
presynaptic termini of neurons (12, 13), with limited expression in glial cells (14). Under 
physiological conditions, α-syn in the cytosol is thought to occur as a monomeric and 
intrinsically disordered protein involved in the regulation of synaptic transmission (15-18), as 
well as homeostasis and neurotransmitter release (19, 20). Moreover, α-syn also interacts 
with synaptic proteins such as phospholipase D2 (21), RAB3a (22) and SNARE complexes 
(19). However, under pathological conditions, α-syn undergoes conformational changes that 
result in the aggregation of the monomer into insoluble intracellular inclusions (23). Previous 
reports have suggested that such conformational changes are initiated when α-syn binds and 
interacts with lipid surfaces to form dimers, ultimately precipitating the formation of 
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oligomers (24, 25). Further aggregation of oligomers leads to the generation of insoluble 
mature fibrils, the major component of LBs (4).  
 
Despite considerable research efforts, relatively little is known about the molecular 
mechanisms underlying α-syn aggregation, the α-syn aggregates with greatest cytotoxic 
qualities and how these relate to the critical impairment or death of neurons thought to 
underlie the clinical phenotype of Lewy body diseases. Currently it is hypothesized that 
prefibrillar oligomers (o-α-syn) are the most toxic forms of α-syn (17, 26-31). However, α-
syn is also subject to post-translational modification, with phosphorylation at serine 129 
(pSer129) being the dominant modification in Lewy bodies (32).  
 
Previous studies investigating α-syn in Lewy body diseases have typically quantified 
α-syn using either histological or biochemical methods in post-mortem brain tissue and 
related these to neuropathological or clinical variables obtained intra vitam. Such studies 
have typically employed pan-α-syn antibodies to fixed tissue sections or tissue lysates, 
generating important data on the progression of α-syn throughout the brain and how its 
expression levels change in different disease conditions. However, studies on fixed tissue 
sections have demonstrated significant burdens of α-syn pathology labelled by pan-α-syn 
antibodies despite an absence of motor or cognitive symptoms (33). A study using enzyme-
linked immunosorbent assay (ELISA) employed pan-α-syn antibodies to the insoluble 
fragment of brain tissue lysates and demonstrated no relationship between insoluble α-syn 
and disease duration or severity of Lewy body pathology in an adjacent brain section (34). 
These studies suggest that using pan-α-syn antibodies, even across tissue fragments extracted 
on the basis of detergent solubility, does not identify forms of α-syn relevant to important 
clinical parameters, such as rate of disease progression. 
 
To better understand the α-syn species present in α-syn aggregates in Lewy body 
disease, we have utilized our novel ELISA platform to quantify and compare t-α-syn, o-α-syn 
and pS129-α-syn in post-mortem brain tissue lysates of different detergent solubility. Here 
we report that aqueous soluble o-α-syn is increased in PD, DLB and AD brain tissue lysates 
but that increased levels of insoluble pS129-α-syn are only observed in cases with dementia 
with Lewy bodies.  
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Materials and methods 
 
Preparation of recombinant α-syn protein  
 
Full-length recombinant human α-syn was expressed in Escherichia coli BL21 (DE3) using 
the bacterial expression vector pRK172. Following expression and sedimentation, the 
bacterial pellets from 1L of TB broth were homogenized and sonicated in 50 ml of high-salt 
buffer (0.75 M NaCl, 10 mM Tris, pH 7.6, 1 mM EDTA) containing a cocktail of protease 
inhibitors (Thermo Scientific), heated to 100°C for 10 min, and centrifuged at 5300 x g for 20 
min. The solution was dialyzed overnight against the buffer used for gel filtration 
chromatography (50 mM NaCl, 10 mM Tris, pH 7.6, 1 mM EDTA), following which, the 
volume was reduced to 5 ml using a Pierce protein concentrator (10K MWCO, ThermoFisher 
Scientific) according to the manufacturer’s instructions. All proteins were purified by size 
exclusion using a Superdex 200 gel filtration column (GE Healthcare). The clean fractions 
were pooled, exchanged with a buffer (10 mM Tris pH 7.6, 25mM NaCl, 1 mM EDTA, 1 
mM PMSF) for ion exchange chromatography by dialysis overnight, and were applied onto a 
HiTrap Q column (GE Healthcare) and eluted in 10 mM Tris pH 7.6 using a linear gradient 
of 0.025-1.0 M NaCl. Purified fractions were pooled, and protein concentrations were 
determined using the Pierce BCA protein assay kit (ThermoFisher Scientific). Purified α-syn 
was phosphorylated at S129 as described previously (35). Briefly, 1 μg of PLK2 protein was 
added to 1.44 mg/ml (100 μM) α-syn in kinase reaction buffer (20 mM HEPES, 1.09 mM 
ATP, 2 mM DTT, 10 mM MgCl2, pH 7.4). Reaction mixture was incubated at 30°C for 24 h. 
 
Sample acquisition 
Frozen post-mortem brain samples from the left frontal cortex (Brodmann area 9) from 
clinically and pathologically diagnosed AD patients (n=15), PD patients (n=15), DLB 
patients (n=16) and controls (n=12) were obtained from Newcastle Brain Tissue Resource, 
Institute of Neuroscience, Newcastle University, UK. Where possible, formalin-fixed, 
paraffin-embedded samples stained against α-syn (KM51, Novocastra, 1:250) or tau (AT8, 
Autogen, 1:1000) were obtained from Brodmann area 9 of the contralateral hemisphere. α-
Syn stained sections were available for 7/15 DLB cases and 3/15 PD cases, and tau stained 
sections were available from 8/15 AD cases. 
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Donors or next of kin provided informed consent to donate tissue and all procedures were 
approved by the local UK National Health Service Research Ethics Committee. The 
demographic details of the samples are given in Table 1. Cases of PD had no evidence of 
dementia, whilst donors with AD or DLB had long standing dementia at death.   
 
Preparation of brain samples 
Frozen brain samples were sequentially extracted as described previously (36). Briefly, 
tissues were homogenized on ice in 5 volumes of TBS buffer (50 mM Tris-HCl, pH 7.4, 175 
mM NaCl) containing 5 mM EDTA and cocktail of protease phosphatase inhibitors (Thermo 
Scientific), and then centrifuged for 30 min at 3000 x g at 4°C with the resulting supernatants 
subsequently referred to as the “aqueous soluble fraction”. The brain lysates were centrifuged 
at 3000 x g using ultracentrifugation to avoid losing any high molecular weight soluble 
oligomers such as protofibrils. Pellets were re-suspended and homogenized in buffer 
containing the mild detergent bicine and 150 mM NaCl (Sigma-Aldrich) and centrifuged at 
3000 x g at 4°C, with the resulting supernatant subsequently referred to as “detergent soluble 
fraction”. The resulting detergent insoluble pellets were solubilized in 8 M Urea/5% SDS and 
will subsequently be referred to as the “insoluble fraction”. Total protein concentration was 
measured using the Pierce BCA assay (ThermoFisher Scientific) and samples stored at -
80°C. 
 
Total α-syn ELISA 
A 384-well ELISA microplate (Nunc MaxiSorp, NUNC) was coated by overnight incubation 
at 4°C with 0.1 μg/ml Syn-140 (sheep anti-α-syn polyclonal antibody) in 200 mM NaHCO3, 
pH 9.6 (50 μl/well). The plate was then washed with PBST and incubated with 100 μl/well of 
blocking buffer (PBST containing 2.5 % gelatin) for 2 h at 37°C. After washing, 50 μl of the 
brain lysate samples (0.1 mg/ml protein) was added to each well, and plates were incubated at 
37°C for 2.5 h. FL-140 (rabbit polyclonal antibody, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), diluted in blocking buffer at 1:1000 dilution, was added to the wells, and 
incubated at 37°C for 1 h. Next, the plate was washed and incubated for 1 h at 37°C with 50 
μl/well of goat anti-rabbit IgG HRP (Jackson ImmunoResearch) diluted in blocking buffer 
(1:20,000). After washing, the plate was incubated with 50 μl/well of an enhanced 
chemiluminescent substrate (SuperSignal ELISA Femto, Pierce Biotechnology, Rockford, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
IL). The chemiluminescence, expressed in relative light units, was immediately measured 
using VICTOR™X3 multilabel plate reader (PerkinElmer). The standard curve for the 
ELISA assay was carried out using serial dilutions of recombinant human α-syn. 
 
Oligomeric α-syn ELISA 
Oligomeric α-syn ELISA was carried out using our previously published protocol (30). 
Briefly, a 384-well ELISA microplate (Nunc MaxiSorp, Nunc) was coated by overnight 
incubation at 4°C with our monoclonal antibody, Syn-O2 (0.2 μg/ml) (37) in 200 mM 
NaHCO3, pH 9.6 (50 μl/well). The plate was washed with PBST and incubated with 100 
μl/well of blocking buffer for 2 h at 37°C. We generated α-syn oligomer standards using our 
previously published method (30). Briefly, α-syn oligomers were prepared by incubating 
fresh α-syn with Ginsenoside Rb1 in PBS at 37°C for 5 days with continuous shaking at 800 
rpm in a thermomixer. Size exclusion chromatography was carried out using an AKTA FPLC 
system and a Superdex 200 column at 4°C, in order to separate soluble oligomers from 
monomers (30). After washing, 50 μl of the brain lysates samples (0.1 mg/ml protein) or 
protein standards were added to each well, and plates were incubated at 37°C for 2.5 h. FL-
140 (rabbit polyclonal antibody, Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 
in blocking buffer at 1:1000, was added to the wells and incubated at 37°C for 2 h. Next, the 
plate was washed and incubated for 2h at 37°C with 50 μl/well of goat anti-rabbit IgG HRP 
(Jackson ImmunoResearch) diluted in blocking buffer (1:15,000). After washing, the plate 
was incubated with 50 μl/well of an enhanced chemiluminescent substrate (SuperSignal 
ELISA Femto, Pierce Biotechnology, Rockford, IL) and measured as previously using a 
VICTOR™X3 multilabel plate reader (PerkinElmer) against a standard curve of serial 
dilutions of recombinant human o-α-syn. 
 
pS129-α-syn ELISA 
A 384-well ELISA microplate (Nunc MaxiSorp, Nunc) was coated by overnight incubation at 
4°C with 0.5 μg/ ml Syn-140 (sheep anti-α-syn polyclonal antibody) in 200 mM NaHCO3, 
pH 9.6 (50 μl/well). The plate was then washed with PBS containing 0.05% Tween-20 
(PBST), and then incubated with 100 μl/well of blocking buffer for 2 h at 37°C. After 
washing, 50 μl of brain lysate samples (0.1 mg/ml protein) was added to each well, and plates 
were incubated at 37°C for 2.5 h. Mouse anti-pS129-α-syn monoclonal antibody diluted in 
the blocking buffer (1:1,000) was added to the wells and incubated at 37°C for 2 h. The plate 
was then washed and incubated for 2 h at 37°C with 50 μl/well of secondary antibody 
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(donkey anti-mouse IgG HRP (Jackson ImmunoResearch)) diluted in blocking buffer 
(1:20,000). After washing, the plate was incubated with 50 μl/well of an enhanced 
chemiluminescent substrate (SuperSignal ELISA Femto) and plates read as previously 
against serial dilutions of recombinant human p-S129-α-syn. 
 
Western blot 
10 μg of total protein from TBS, detergent or urea/SDS –soluble fractions of brain lysates 
fractions and 10 ng of recombinant α-syn or pS129-α-syn were prepared in the loading buffer 
(2%SDS, 0.25 M Tris-HCL, pH 6.8, 10% glycerol, 0.01% bromophenol blue, 5% b-
mercaptoethanol), before loading onto 15% SDS-PAGE gels and separated by electrophoresis 
at 100 V for 90 minutes. The proteins were subsequently transferred on to a nitrocellulose 
membrane (100 V for 1 hour). The membrane was boiled in PBS for 5 minutes and blocked 
with blocking buffer (5% skimmed milk in PBS-T) for 1 hr at room temperature followed by 
incubation with primary antibodies (Syn-140, 50 ng/ml in blocking buffer or rabbit antibody 
against pS129-α-syn (ab51253, Abcam, 20 ng/ml) overnight at 4°C. After washing with 
PBST, the membrane was incubated for 1 hr with HRP-conjugated donkey anti-sheep IgG 
(1:200,000 in blocking buffer, Jackson ImmunoResearch Laboratories Inc., USA) or HRP-
conjugated goat anti-rabbit (1/100,000, Jackson ImmunoResearch Laboratories Inc., USA). 
Following an additional washing step with PBST, the membranes were developed with 
SuperSignal West Femto substrate (Pierce Biotechnology, Rockford, USA) and the signal 
detected using Syngene Pxi 9 Gel Doc System. 
 
Semi-quantitative analysis of histopathology  
We evaluated the burden of α-syn and tau in tissue sections obtained from the contralateral 
hemisphere of a sub-set of cases, for which Brodmann area 9 had been stained for routine 
diagnostic evaluation. The severity of α-syn and tau pathology was determined using 
previously published consensus methods for semi-quantitative analysis of neurodegenerative 
pathologies (38, 39).  
 
Statistical analysis 
Statistical significance for the comparison of the levels of α-syn between the groups was 
analysed by one-way analysis of variance (ANOVA) with a Bonferroni correction applied to 
attenuate false-positives arising from multiple comparisons using the SPSS statistics package. 
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The relationship between protein quantities established by ELISA was compared to semi-
quantitative analysis of pathological severity using Spearman’s rho on SPSS statistics 
package. For all analyses, p values < 0.05 were considered significant.   
 
 
Results 
The aqueous soluble fraction is dominated by α-syn oligomers and protofibrils in PD, 
DLB and AD 
In order to quantify the levels of α-syn, we employed a recently developed highly specific 
ELISA (30, 40). This ELISA uses a capture antibody (Syn-O2) that we generated in-house 
and have demonstrated through extensive biochemical assays, including Thioflavin-T, dot 
blot, EM and ELISA recognizes early α-synuclein oligomers and protofibrils but not the 
soluble monomer (37). T-α-syn levels in the aqueous soluble fraction were not significantly 
different across groups (F=0.587, df=3, p=0.626; Fig. 1a). However, significant differences in 
the levels of soluble α-syn oligomers/protofibrils in the aqueous soluble fraction were 
observed (F=6.672, df=3, p=0.001) with PD (p=0.009), DLB (p=0.004), and also AD 
(p=0.001), significantly increased compared to control (Fig.1b). pS129 was not significantly 
different across groups in the aqueous soluble fraction (F=1.882, df=3, p=0.144; Fig.1 c). 
However, the percentage of o-α-syn relative to t-α-syn was only significantly higher in AD 
(p=0.009) and DLB (p=0.033) compared to control (Fig. 1 d) though there were no 
significant group differences in the proportion of pS129-α-syn relative to t-α-syn (F=1.321, 
df=3, p=0.277; Fig. 1e). 
 
The detergent soluble fraction contains high levels of pS129-α-syn in PD and AD 
In the detergent soluble fraction, t-α-syn (F=2.332, df=3, p=0.085; Fig. 2a) and o-α-syn 
(F=1.941, df=3, p=0.134; Fig. 2b) were not significantly different across groups.  
pS129-α-syn was significantly different across groups in the detergent soluble phase 
(F=7.888, df=3, p<0.001), with higher values recorded in AD (p=0.037) and PD (p<0.001) 
brain lysates compared to control (Fig. 2c). There was no significant difference in detergent 
soluble pS129-α-syn levels in DLB brain lysates compared to controls.  
No differences were observed in the ratio of o-/t- α-syn across experimental groups (F=2.575, 
df=3, p=0.064; Fig. 2d). The proportion of pS129-/t- α-syn was significantly increased 
(F=3.283, df=3, p=0.028), but only in PD compared to control (p=0.024; Fig. 2 e). 
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The insoluble fraction of DLB brain tissue lysates predominantly contains pS129-α-syn 
In solubilized urea/SDS samples, the levels of t-α-syn in DLB were not significantly different 
across groups (F=0.664, df=3, p=0.578; Fig. 3a). However, insoluble pS129-α-syn levels 
were significantly higher (F=7.050, df=3, p<0.001) only in DLB compared to control 
(p=0.002; Fig. 3b). DLB were also significantly higher than PD (p=0.012) and AD (p=0.002).  
There were significantly higher ratios (F=9.747, df=3, p<0.001) of pS129-α-syn/t-α-syn in 
DLB compared to control (p<0.001), PD (p=0.004) and AD (p<0.001; Fig 3c). 
 
Western blot to detect total- and pS129-α-syn  
To further investigate whether we can distinguish different disease groups based on α-syn 
levels in different fractions of the brain lysates, we also carried out western blot analysis. To 
detect t-α-syn we used Syn-140 sheep polyclonal antibody against full length α-syn, and 
phospho-specific antibody for the detection of pS129-α-syn. In all extracts and in all cases, 
Syn-140 antibody detected α-syn with molecular weight of ~14 kDa with virtually uniform 
expression across cases (Fig. 4 a-d), consistent with the results of our ELISA.  
Western blot revealed pS129-α-syn as virtually absent from control cases in all tissue 
fragments (Fig. 4 a-d), consistent with ELISA results. However, consistent with our findings 
from ELISA, we noted expression of pS129-α-syn in detergent and insoluble tissue fragments 
from cases with Lewy body disease, and in the detergent soluble fraction of AD cases 
without Lewy body disease (Fig. 4 a-d).    
 
Comparison to histological findings 
Correlational statistical analysis demonstrated no relationships, nor trends towards 
relationships, between the semi-quantitative burden of α-syn pathology and any α-syn species 
determined in PD and DLB cases (Fig. 5 a-f). Furthermore, no relationship was observed 
between tau pathology in AD cases and any α-syn species, with the exception of detergent-
soluble pS129-α-syn and tau (rs=0.743, N=8, p=0.035). 
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Discussion 
 
Using tissue lysates from the frontal cortex of PD, DLB, AD and aged control cases we have 
demonstrated that aqueous soluble α-syn oligomers and protofibrils is elevated in the frontal 
cortex of PD and AD cases without neocortical Lewy body disease. Furthermore, we have 
demonstrated that a greater proportion of pS129-α-syn is insoluble in DLB cases, but that 
detergent soluble pS129-α-syn is increased in PD and AD cases relative to controls. Taken 
together, these findings indicate that elevated levels of detergent-soluble pS129-α-syn is 
found across several neurodegenerative disorders, including those without Lewy bodies, but 
only cases with neocortical Lewy body disease have elevated levels of insoluble pS129-α-
syn.  
Aqueous soluble α-syn oligomers/protofibrils was significantly increased in PD and DLB 
cases. It is noteworthy that α-syn oligomers/protofibrils was increased in PD cases without 
substantial neocortical pathology, perhaps indicating that disease-relevant α-syn oligomers 
and protofibrils precedes the formation of Lewy bodies, and may relate to the mild cognitive 
dysfunction in PD patients that typically precedes clinically overt dementia. As soluble α-syn 
oligomers and protofibrils are thought to be a particularly neurotoxic form of α-syn (27, 28, 
30, 31, 41-47), such a proposition may be consistent with previous studies demonstrating 
neuronal loss (47) and changes to α-syn protein (48; 49) preceding solubility changes and 
Lewy body formation. However, a linear progression of α-syn aggregation to states of 
increasing insolubility is not consistent with increased levels of soluble α-syn oligomers and 
protofibrils in DLB in the present study, as these cases have substantial burdens of Lewy 
body pathology and any soluble α-syn oligomers and protofibrils would have been expected 
to already have aggregated into more insoluble species. One may speculate that increased 
levels of soluble α-syn oligomers and protofibrils in DLB, despite significant burdens of 
Lewy bodies, suggests stabilization of o-α-syn without further aggregation into Lewy bodies, 
which has previously been described in PD (51).   
It is perhaps unsurprising that DLB cases with neocortical pathology had higher proportions 
of insoluble pS129-α-syn as they manifest neocortical Lewy body pathology. However, we 
did not find a relationship between the severity of neocortical Lewy body deposition and 
quantities of insoluble pS129-α-syn, perhaps reflecting the heterogeneous nature of 
aggregates labelled by pan-α-syn antibodies for immunohistochemistry. DLB cases had no 
significant increase in detergent soluble pS129-α-syn, perhaps suggesting these have 
aggregated further into more insoluble aggregates, as indicated by increased levels of 
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insoluble pS129-α-syn in DLB cases. In contrast, PD cases without significant neocortical 
Lewy body pathology had higher levels of detergent soluble pS129-α-syn compared to 
controls, but no increase in insoluble α-syn, perhaps indicating that increasingly insoluble 
pS129-α-syn precedes the formations of histologically manifest α-syn pathology.     
Despite not manifesting neocortical Lewy body pathology, AD cases in the present study had 
increased levels of aqueous soluble α-syn oligomers/protofibrils and detergent soluble pS129-
α-syn. Although these findings were unexpected, α-syn can interact with tau, and both are 
suggested to have a synergistic relationship (52, 53). It is tempting to speculate that small 
aggregates of o- and pS129- α-syn may be related to the accumulation of tau pathology, a 
relationship suggested by the significant positive correlation between detergent soluble 
pS129-α-syn and tau pathology in the presently evaluated AD cases. Consistent with this 
proposition, α-syn and tau can both be phosphorylated by Polo-like kinase 2 (PLK2), and 
PLK2 is increased in AD brain tissue (54). Nevertheless, the evaluated cohorts are relatively 
small and validation in larger cohorts is important, particularly to evaluate the relationship 
with tau pathology. 
Quantification of α-syn pathology from the same region from the contralateral hemisphere 
demonstrated no relationship whatsoever between Lewy body pathological burden and any 
sub-type of α-syn determined by ELISA. Although this finding was surprising, it is possible 
that different hemispheres used to evaluate α-syn by histology and biochemistry, 
respectively, may have had different burdens of relevant pathologies. Nevertheless, such a 
finding is not without precedent even when analyses are conducted in the same hemisphere, 
as a previous study has also demonstrated no relationship between detergent soluble α-syn 
and Lewy body pathological burden (34). One may argue that the lack of a relationship 
between Lewy body pathology severity identified with a pan-α-syn antibody and quantitation 
of α-syn sub-types in our study illustrates the considerable heterogeneity amongst α-syn 
aggregates in Lewy body diseases, thus underlining the strength of our approach in 
evaluating distinct sub-types of α-syn.   
Many previous studies have extracted tissue fragments on the basis of detergent solubility to 
evaluate differences in levels of α-syn using a pan-α-syn antibody. It is notable that when we 
evaluated t-α-syn using a pan-α-syn antibody across tissue fractions we did not observe any 
significant differences across groups. We only observed changes at the group level when we 
used antibodies specifically recognizing sub-types of α-syn, such as o-α-syn or pS129-α-syn. 
These findings further suggest that pan-α-syn antibodies do not capture the diversity of α-syn 
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aggregates and may explain why previous studies have not detected relationships between α-
syn quantity and important clinical variables, such as disease duration (34).   
A major strong point of our study includes employing a panel of α-syn ELISA recognizing 
distinct sub-types of the protein to tissue lysates isolated on the basis of solubility. This 
approach is rarely used in the literature and, thus, we have generated important data on the 
diversity of α-syn aggregates, both in Lewy body diseases and in AD. However, a weakness 
of our study is the relatively small group sample sizes and the limited number of cases for 
which we had histological sections from the contralateral hemisphere to evaluate pathological 
burden. The latter was based largely upon Brodmann area 9 either not being evaluated in a 
routine diagnostic setting or the use of different antibodies over time. Nevertheless, there was 
no suggestion whatsoever of any relationship between Lewy body pathology and any sub-
types of α-syn quantified in the present study by ELISA. 
In summary, using a novel platform of ELISA recognizing distinct sub-types of α-syn to 
brain tissue lysates of differing solubility we have demonstrated significant relative levels of 
α-syn sub-types in different neurodegenerative disorders. Notably, we demonstrated no 
difference in t-α-syn in any tissue fragment; however, aqueous soluble o-α-syn was increased 
in the frontal cortex of DLB, PD and AD. Furthermore, detergent soluble pS129-α-syn was 
increased in both PD and AD, whilst insoluble pS129-α-syn was increased in DLB. Together 
these findings provide important data on the heterogeneous nature of α-syn aggregates in 
Lewy body diseases and other neurodegenerative disorders and demonstrate the substantial 
complexity underlying α-syn aggregation and the evaluation of its clinical and pathological 
relevance in post-mortem studies. 
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Figure legends 
Figure 1.  
Detection of α-syn species in brain lysates from aqueous soluble fractions of AD (solid 
circles), PD (solid squares), DLB (solid triangles) and control (solid inverted triangles) 
samples. Total-, oligomeric- and phosphorylated at Ser129-α-syn (t-, o- and pS129-α-syn) 
were detected using t-ELISA (a), o-ELISA (b) and p-ELISA (c) respectively. The % ratio of 
o-α-syn over t-α-syn (d) or pS129-α-syn over t-α-syn (e) were also calculated. The aqueous 
soluble fraction contains significantly high levels of o-α-syn in AD, PD and DLB compared 
to controls.   
 
Figure 2.  
Detection of α-syn species in brain lysates from detergent soluble fractions of AD (solid 
circles), PD (solid squares), DLB (solid triangles) and controls (solid inverted triangles) 
samples. t-, o- and pS129-α-syn were detected using t-ELISA (a), o-ELISA (b) and p-ELISA 
(c) respectively. The % ratios of o-α-syn over t-α-syn (d) or pS129-α-syn over t-α-syn (e) 
were also calculated. The detergent soluble fraction contains significantly high levels of 
pS129-α-syn in AD and PD compared to controls.  
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Figure 3.  
Detection of α-syn species in brain lysates from urea/SDS soluble fractions of AD (solid 
circles), PD (solid squares), DLB (solid triangles) and control (solid inverted triangles) 
samples. t- and pS129-α-syn were detected using t-ELISA (a) and p-ELISA (b) respectively. 
The % ratios of pS129-α-syn over t-α-syn (c) were also calculated. The urea/SDS soluble 
fraction contains significantly high levels of pS129-α-syn in DLB and PD compared to 
controls. 
 
Figure 4.  
Western blot analysis for detection of t- or pS129-α-syn in brain lysates form DLB (a), PD 
(b), AD (c), and controls (d). 10 μg of total protein from TBS, detergent or urea/SDS soluble 
brain lysates fractions and 10 ng of recombinant α-syn or pS129-α-syn were used for western 
transfer and probed with either Syn-140 or rabbit mAb against pS129-α-syn (ab51253, 
Abcam). PS129-α-syn was detected in detergent and urea/SDS soluble fraction from DLB 
and PD samples (a, b). Whereas, few samples in the AD sample also showed some reactivity 
to pS129-α-syn antibody (ab51253) in urea/SDS soluble fraction (c). 
 
Figure 5.  
Representative staining demonstrating very severe (a), moderate (b) and mild (c) alpha-
synuclein pathology, and severe (d), moderate (e) and mild (f) tau pathology. Scale bars 
50um (a-c) and 100um (d-f.) 
 
Table 1. Demographic details of the brain samples 
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Group      
 
AD  
 
PD  
 
DLB  
 
Control  
 
N 
 
15 
 
15 
 
16 
 
12 
Age at death (years)
* 
79 ± 6 76 ± 7  77 ± 6 70 ± 16 
Male: Female 8:7 9:6 12:4 6:6 
Postmortem delay (hours)
* 
22 ± 9 24 ± 11 19 ± 9 24 ± 22 
     
 
 
Table 1. Demographic details of the brain samples 
*Values represent mean ± standard deviation 
AD- Alzheimer’s disease, PD- Parkinson’s disease, DLB- Dementia with Lewy bodies 
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